InvestorsHub Logo
Followers 56
Posts 5064
Boards Moderated 0
Alias Born 11/11/2014

Re: None

Thursday, 10/20/2016 8:23:17 AM

Thursday, October 20, 2016 8:23:17 AM

Post# of 514
News Out!! - More positive updates from Clinical trials for Basal Cell Carcinoma

HedgePath Pharmaceuticals Announces Further Positive Interim Data in its Phase II(b) Cancer Trial


18 subjects with Basal Cell Carcinoma Nevus Syndrome who had 231 surgically eligible tumors complete 16 weeks of dosing with SUBA™-Itraconazole

Second interim analysis shows a statistically significant mean target tumor burden reduction (P<0.0001) and 11 of 18 trial subjects to date achieving a 30% or greater reduction in target tumor burden

Full Article: http://www.prnewswire.com/news-releases/hedgepath-pharmaceuticals-announces-further-positive-interim-data-in-its-phase-iib-cancer-trial-300348148.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INTI News